CY1112551T1 - Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης - Google Patents

Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης

Info

Publication number
CY1112551T1
CY1112551T1 CY20111100823T CY111100823T CY1112551T1 CY 1112551 T1 CY1112551 T1 CY 1112551T1 CY 20111100823 T CY20111100823 T CY 20111100823T CY 111100823 T CY111100823 T CY 111100823T CY 1112551 T1 CY1112551 T1 CY 1112551T1
Authority
CY
Cyprus
Prior art keywords
activity
derivatives
glycosaminoglycans
inhibitors
partially released
Prior art date
Application number
CY20111100823T
Other languages
English (en)
Inventor
B Casu
G Torri
A Naggi
Giuseppe Giannini
Claudio Pisano
Sergio Penco
Original Assignee
Sigma-Tau Research Switzerland S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Research Switzerland S.A. filed Critical Sigma-Tau Research Switzerland S.A.
Publication of CY1112551T1 publication Critical patent/CY1112551T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)

Abstract

Περιγράφονται μερικώς αποσουλφωμένα παράγωγα γλυκοζαμινο-γλυκάνης, ιδίως η ηπαρίνη, και πιο συγκεκριμένα ενώσεις του τύπου (I) όπου οι ομάδες U, R και R1 έχουν τις σημασίες που υποδεικνύονται στην περιγραφή. Τα εν λόγω παράγωγα γλυκοζαμινογλυκάνης διαθέτουν αντι-αγγειογόνο και ανασταλτική της ηπαρανάσης δραστικότητα και στερούνται αντιπηκτικής δραστικότητας.
CY20111100823T 2001-09-12 2011-08-29 Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης CY1112551T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01972468A EP1427427B1 (en) 2001-09-12 2001-09-12 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
PCT/IT2001/000472 WO2003022291A1 (en) 2001-09-12 2001-09-12 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Publications (1)

Publication Number Publication Date
CY1112551T1 true CY1112551T1 (el) 2016-02-10

Family

ID=11133723

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100823T CY1112551T1 (el) 2001-09-12 2011-08-29 Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης
CY20131100685T CY1114544T1 (el) 2001-09-12 2013-08-09 Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100685T CY1114544T1 (el) 2001-09-12 2013-08-09 Παραγωγα πληρως ν-αποθειωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονικη δραστικοτητα και δεν επιφερουν αντιθρομβωτικο αποτελεσμα

Country Status (20)

Country Link
US (1) US20050137167A1 (el)
EP (2) EP2343077B1 (el)
JP (1) JP2005506326A (el)
KR (1) KR100855331B1 (el)
CN (1) CN1547477B (el)
AT (1) ATE511846T1 (el)
AU (1) AU2001292231B2 (el)
BR (1) BR0117124A (el)
CA (1) CA2457719C (el)
CY (2) CY1112551T1 (el)
CZ (1) CZ307433B6 (el)
DK (1) DK1427427T3 (el)
ES (2) ES2367778T3 (el)
HK (1) HK1069537A1 (el)
HU (1) HU230385B1 (el)
MX (1) MXPA04002217A (el)
PT (2) PT2343077E (el)
SI (1) SI1427427T1 (el)
SK (1) SK288335B6 (el)
WO (1) WO2003022291A1 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819833A (zh) * 2004-03-29 2006-08-16 克霖固鲁制药股份有限公司 促进hgf产生的含肝素类寡糖的药剂
WO2008046162A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US9351992B2 (en) 2007-11-02 2016-05-31 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
FI20085308A0 (fi) * 2008-04-11 2008-04-11 Polysackaridforskning I Uppsal Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2550004A4 (en) * 2010-03-12 2014-07-02 Univ Australian SUBSTITUTE THERAPY WITH HEPARAN SULFATE
JP5982361B2 (ja) 2010-04-16 2016-08-31 モメンタ ファーマシューティカルズ インコーポレイテッド 組織標的化方法
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
FR2970969B1 (fr) * 2011-01-27 2013-10-18 Sanofi Aventis Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique
KR101522604B1 (ko) * 2013-03-21 2015-05-26 대한민국 곤충 글라이코자미노글라이칸 유래 헤파린 단편 및 이의 제조 방법
RU2700877C2 (ru) * 2013-05-16 2019-09-23 Эдженси Фо Сайенс, Текнолоджи Энд Ресёрч Гепарансульфаты
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
ITLO20130005A1 (it) * 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) * 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
CN107645954A (zh) 2015-03-06 2018-01-30 清算中的利迪安特生物科学股份有限公司 多发性骨髓瘤的罗尼哌他组合治疗
CA3046997A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
EP3601312A4 (en) * 2017-03-23 2020-12-23 Victoria Link Limited GLYCOMIMETIC COMPOUNDS OF HEPARAN SULPHATE AND THEIR PHARMACEUTICAL AND COSMETIC USES
EP3388439A1 (en) 2017-04-11 2018-10-17 Leadiant Biosciences SA Biotin-conjugated n-acetyl glycol split heparin
US11225531B2 (en) 2018-02-02 2022-01-18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Glycosaminoglycan derivative and preparation method therefor and use thereof
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
WO2021128253A1 (zh) * 2019-12-27 2021-07-01 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
JPS62265998A (ja) * 1986-03-10 1987-11-18 ボ−ド　オブ　リ−ジエンツ　ザ　ユニヴア−シテイ　オブ　テキサス　システム ヘパラン硫酸エンドグリコシダーゼアッセイ
IE61758B1 (en) 1986-05-23 1994-11-30 Daiichi Seiyaku Co Use of a sulfated polysaccharide
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
WO1988001280A1 (en) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
IL85145A (en) 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
CZ195193A3 (en) 1992-09-25 1994-04-13 Lilly Co Eli Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5399667A (en) 1993-03-05 1995-03-21 Washington University Thrombospondin receptor binding peptides
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
WO1995005182A1 (en) 1993-08-13 1995-02-23 Glycomed Incorporated Bridged oligosaccharides and sulfated derivatives thereof
EP0722326A4 (en) 1993-10-07 1999-10-06 Glycomed Inc HIGHLY SULFATED MALTOOLIGOSSACCHARIDES WITH HEPARIN-LIKE PROPERTIES
US5739115A (en) 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
JPH09512822A (ja) 1994-05-06 1997-12-22 グリコメド・インコーポレイテッド Ｏ−脱硫酸化ヘパリン誘導体とその製造法および使用
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
DE19955803A1 (de) 1999-11-19 2001-05-23 Knoll Ag Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
AU3078800A (en) * 2000-01-25 2001-08-07 Nippon Eisei Center Co., Ltd. Earthquake-proofing reinforcing metal fitting

Also Published As

Publication number Publication date
PT1427427E (pt) 2011-09-13
HU230385B1 (hu) 2016-03-29
ES2367778T3 (es) 2011-11-08
WO2003022291A1 (en) 2003-03-20
EP2343077B1 (en) 2013-07-17
PT2343077E (pt) 2013-08-29
CZ2004255A3 (cs) 2004-11-10
EP1427427B1 (en) 2011-06-08
HUP0401693A3 (en) 2009-06-29
CA2457719A1 (en) 2003-03-20
ES2431362T3 (es) 2013-11-26
BR0117124A (pt) 2004-09-28
HK1069537A1 (en) 2005-05-27
MXPA04002217A (es) 2004-07-08
KR20040048404A (ko) 2004-06-09
JP2005506326A (ja) 2005-03-03
CA2457719C (en) 2012-01-03
EP1427427A1 (en) 2004-06-16
CY1114544T1 (el) 2016-10-05
CN1547477A (zh) 2004-11-17
US20050137167A1 (en) 2005-06-23
KR100855331B1 (ko) 2008-09-04
DK1427427T3 (da) 2011-09-19
EP2343077A1 (en) 2011-07-13
CN1547477B (zh) 2010-12-22
CZ307433B6 (cs) 2018-08-22
ATE511846T1 (de) 2011-06-15
SI1427427T1 (sl) 2011-10-28
SK288335B6 (sk) 2016-02-02
HUP0401693A2 (hu) 2004-12-28
SK1602004A3 (en) 2004-08-03
AU2001292231B2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
CY1112551T1 (el) Παραγωγα μερικως αποσουλφωμενων γλυκοζαμινογλυκανων ως αναστολεις ηπαρανασης, τα οποια διαθετουν αντιαγγειογονο δραστικοτητα και στερουνται αντιπηκτικης επιδρασης
DK1268558T3 (da) Derivater af delvist desulfaterede glycosaminoglycaner forsynet med antiangionisk aktivitet og uden antikoagulerende virkning
NO20006323D0 (no) Glykopeptidderivater og farmasöytiske sammensetninger som inneholder disse
DE60333937D1 (de) Substituierte quinazolinone verbindungen
NO20055565D0 (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
DK1474395T3 (da) Nicotinamidderivater, der er nyttige som p38-inhibitorer
ATE407967T1 (de) Nukleierungsmittel
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
CY1109219T1 (el) Ινδολο, αζαινδολο και σχετικα ετεροκυκλικα αμιδοπιπεραζινο παραγωγα
NO20025954D0 (no) Glykopeptidfosfonatderivater
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
NO20051844L (no) Piperazinderivater og fremgangsmate for anvendelse derav.
NO20071871L (no) Fosfoindoler som HIV-inhibitorer.
NZ507835A (en) Heterocyclic derivatives which inhibit factor XA
ATE386742T1 (de) Imidazonaphthyridine
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
DK0971922T3 (da) Tetrahydropyrido-forbindelser
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
IL173629A0 (en) Imidazo(4,5-b) pyridine derivatives and pharmaceutical compositions containing the same
TR200001026T2 (tr) Nötrofil elastaz inhibitörü olarak pirolopirolon türevleri.
ATE269313T1 (de) Tryptase-inhibitoren